Thanks. I too think softer sell is better, but for more than just ‘patient disappointment’ reasons. Eg FDA may force a change, which will be unpleasant especially if very public. And they have an important sBLA in review by the FDA, so pissing them off seems unwise.
RVNC can certainly promote Daxxify using published data from clinical trials.
This is not clear to me. Historically this was questionable, but perhaps the Amarin case changed that? Not something I’ve tracked in detail since the Amarin case, so …?
My two cents is that with the inflation squeeze, there may be fewer “young adopters” trying out Botox of any sort to prevent developing wrinkles in the future.
At one point, it seemed like the next big thing for the younger generation, but with budgets getting tighter, cosmetic surgery/applications probably seems like a lower priority for many people.
Market Data 
Markets 
AI
